Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
Axon Likely to Deliver In-Line Q3 Results, RBC Says

Axon Likely to Deliver In-Line Q3 Results, RBC Says

MT newswireMT newswire2026/09/29 15:56
11:56 AM EDT, 09/29/2026 (MT Newswires) -- Axon Enterprise (AXON) is expected to report in-line Q3 results amid a seasonally soft quarter, with focus likely to be on its margin, RBC Capital Markets said in a Monday note. The note said adjusted EBITDA margin is expected to trough in Q3 at 24.5%, with margin expansion resuming in Q4 as the company scales to meet its 2026 guidance of 25.5%. The report said Q3 estimate reflects several transitory headwinds including elevated component costs, the absence of a one-time tariff refund, and continued mix pressure. The note also pointed to a stock sell-off intra-quarter on the back of its convertible offering and De-Flock narrative. "We view this as near-term noise -- fundamentals remain strong, creating an attractive entry point," the report said. RBC kept its outperform rating with a price target of $735. Price: 421.05, Change: -3.70, Percent Change: -0.87
0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

Former BioNTech executive leads Bambusa Therapeutics (BBTX.US) in sprint to Nasdaq, "boosting" eczema drug trials

Bambusa Therapeutics Inc. has filed for an initial public offering, planning to raise funds for clinical trials of treatments for eczema and other inflammatory diseases.

智通财经•2026/10/10 06:21